DK1272195T3 - Anvendelse af fulvestrant til behandling af resistent brystcancer - Google Patents

Anvendelse af fulvestrant til behandling af resistent brystcancer

Info

Publication number
DK1272195T3
DK1272195T3 DK01917289T DK01917289T DK1272195T3 DK 1272195 T3 DK1272195 T3 DK 1272195T3 DK 01917289 T DK01917289 T DK 01917289T DK 01917289 T DK01917289 T DK 01917289T DK 1272195 T3 DK1272195 T3 DK 1272195T3
Authority
DK
Denmark
Prior art keywords
fulvestrant
treatment
breast cancer
resistant breast
resistant
Prior art date
Application number
DK01917289T
Other languages
Danish (da)
English (en)
Inventor
Beat Thurlimann
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1272195(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1272195T3 publication Critical patent/DK1272195T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK01917289T 2000-04-05 2001-04-02 Anvendelse af fulvestrant til behandling af resistent brystcancer DK1272195T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0008172.9A GB0008172D0 (en) 2000-04-05 2000-04-05 Therapy

Publications (1)

Publication Number Publication Date
DK1272195T3 true DK1272195T3 (da) 2006-01-16

Family

ID=9889101

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01917289T DK1272195T3 (da) 2000-04-05 2001-04-02 Anvendelse af fulvestrant til behandling af resistent brystcancer

Country Status (28)

Country Link
US (2) US20030158166A1 (enExample)
EP (2) EP1586323A1 (enExample)
JP (1) JP2003528919A (enExample)
KR (1) KR100757764B1 (enExample)
CN (1) CN1431905A (enExample)
AT (1) ATE306270T1 (enExample)
AU (2) AU2001244372B2 (enExample)
BR (1) BR0109789A (enExample)
CA (1) CA2403608A1 (enExample)
CH (1) CH1272195H1 (enExample)
CZ (1) CZ303096B6 (enExample)
DE (1) DE60113975T2 (enExample)
DK (1) DK1272195T3 (enExample)
EE (1) EE05026B1 (enExample)
ES (1) ES2248300T3 (enExample)
GB (1) GB0008172D0 (enExample)
HU (1) HU230064B1 (enExample)
IL (2) IL151932A0 (enExample)
IS (1) IS2869B (enExample)
MX (1) MXPA02009744A (enExample)
NO (1) NO329949B1 (enExample)
NZ (1) NZ539603A (enExample)
PL (1) PL201175B1 (enExample)
RU (1) RU2265438C2 (enExample)
SK (1) SK287779B6 (enExample)
UA (1) UA80388C2 (enExample)
WO (1) WO2001074366A1 (enExample)
ZA (1) ZA200207538B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0210898A (pt) * 2001-07-07 2004-06-22 Astrazeneca Ab Formulação farmacêutica, dose unitária da mesma, uso de pulvestrante na preparação de uma formulação farmacêutica, e, seringa ou frasco estéril
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
US8557863B2 (en) * 2005-09-27 2013-10-15 Robert Benson Aylor Suppression and prevention of tumors
US8324194B2 (en) * 2005-11-22 2012-12-04 Incyte Corporation Combination therapy for the treatment of cancer
WO2007143600A2 (en) * 2006-06-05 2007-12-13 Incyte Corporation Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
KR20140048881A (ko) * 2011-05-09 2014-04-24 유니버시티 오브 버지니아 페이턴트 파운데이션 암 치료 조성물 및 방법
BR112013029758A2 (pt) 2011-05-20 2018-10-09 Capital, Business Y Gestion De Finanzas S.L. composição farmacêutica
WO2015106094A1 (en) * 2014-01-10 2015-07-16 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
US9421264B2 (en) * 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
TWI878810B (zh) 2017-09-11 2025-04-01 美商阿托薩醫療公司 製造及使用因多昔芬(endoxifen)之方法
CA3101421C (en) * 2018-05-24 2024-06-18 Kashiv Biosciences, Llc Prodrugs of fulvestrant
CA3145867A1 (en) 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
WO2021174195A2 (en) * 2020-02-29 2021-09-02 The University Of Vermon Use of thyromimetics for the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Also Published As

Publication number Publication date
EE05026B1 (et) 2008-06-16
AU4437201A (en) 2001-10-15
DE60113975D1 (de) 2006-02-23
IS6576A (is) 2002-10-01
PL201175B1 (pl) 2009-03-31
US20030158166A1 (en) 2003-08-21
EP1586323A1 (en) 2005-10-19
EP1272195A1 (en) 2003-01-08
IL151932A0 (en) 2003-04-10
JP2003528919A (ja) 2003-09-30
IS2869B (is) 2014-03-15
RU2265438C2 (ru) 2005-12-10
CH1272195H1 (enExample) 2019-10-15
BR0109789A (pt) 2003-01-21
ATE306270T1 (de) 2005-10-15
NO20024735L (no) 2002-11-27
CZ20023309A3 (cs) 2003-02-12
MXPA02009744A (es) 2004-02-26
HU230064B1 (hu) 2015-06-29
ES2248300T3 (es) 2006-03-16
CN1431905A (zh) 2003-07-23
NO20024735D0 (no) 2002-10-02
EP1272195B1 (en) 2005-10-12
HUP0300339A2 (hu) 2003-06-28
US20110183949A1 (en) 2011-07-28
DE60113975T2 (de) 2006-06-22
AU2001244372B2 (en) 2006-02-16
ZA200207538B (en) 2003-12-19
CZ303096B6 (cs) 2012-04-04
KR20030007501A (ko) 2003-01-23
HUP0300339A3 (en) 2009-01-28
KR100757764B1 (ko) 2007-09-12
PL357936A1 (en) 2004-08-09
CA2403608A1 (en) 2001-10-11
NZ539603A (en) 2008-02-29
EE200200574A (et) 2004-04-15
GB0008172D0 (en) 2000-05-24
WO2001074366A1 (en) 2001-10-11
SK14292002A3 (sk) 2003-08-05
NO329949B1 (no) 2011-01-31
SK287779B6 (sk) 2011-09-05
IL151932A (en) 2007-07-04
UA80388C2 (en) 2007-09-25
HK1051498A1 (en) 2003-08-08

Similar Documents

Publication Publication Date Title
DK1272195T3 (da) Anvendelse af fulvestrant til behandling af resistent brystcancer
KR970704430A (ko) 전립선 질환, 자궁내막증 및 비만증의 치료를 위한 드롤록시펜의 용도(use of droloxifene for the treatment of prostatic diseases endometriosis and obesity)
DE60138611D1 (de) Synergistische kombinationstherapie zur krebsbehandlung
DK1083889T3 (da) Tetrahydronaphthalenforbindelser og deres anvendelse til behandling af neurodegenerative sygdomme
DE60138129D1 (de) Apparat zur behandlung von zähnen
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
DK1382340T3 (da) Terapeutiske anvendelser af dehydroepiandrosteron til behandling af reduceret libido og osteoporose
DK1446012T3 (da) Bakteriolytisk kombinationsterapi til behandling af tumorer
EE200100480A (et) Ksenoon kasutamiseks närvimürgistuste ravis
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
DK1716853T3 (da) Behandling af cancer i menneskekroppen ved anvendelse af ET743
ATE346614T1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
DK1432417T3 (da) Substituerede imidazolforbindelser og deres anvendelse til behandling af cancer
DE60223576D1 (de) Hautbehandlungszusammensetzung
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
NO20033123D0 (no) Terapeutisk hinnedannende sammensetning og behandlingsplan derav
NO20053626L (no) Blanding omfattende en kombinasjon av en aromataseinhibitor, et progestin og et ostrogen for anvendelse av behandling av endomeriose
DE60221068D1 (de) Gerät zur tiefenwirksamen Hauttherapie
IS6707A (is) Efnablanda til forvarna og meðhöndlunar á krabbameini
NO20005548D0 (no) Mykobakterieinhibitorer
NO20010630D0 (no) Krummet trapp og trappetrinn for krummet trapp
ATE297745T1 (de) Chemische modifizierung von harn von säugern
DK1379242T3 (da) Fremgangsmåde til behandling af cancer og sammensætninger til anvendelse derved
IT1314372B1 (it) Procedimento e dispositivo elettronico per il trattamento dellaceramica per protesi dentale e/o similari.
SI1272195T1 (sl) Uporaba fulvestranta pri zdravljenju rezistentnega raka dojk